YOLFTbeta
Shanghai Allist Pharmaceuticals Co. Ltd. A

Shanghai Allist Pharmaceuticals Co. Ltd. A

688578 · SHG · Healthcare / Biotechnology

81.62CNY-1.45 (-1.75%)

Price History

Full chart

Market Stats

Previous Close83.07
Open83.19
Day Range81.62 – 83.80
52-Week Range78.38 – 137.54
Volume3.91M
Market Cap50.21B
P/E (TTM)18.78
Forward P/E0.00
EPS5.94
Dividend Yield1.08%
Beta0.01
50-Day Avg111.58
200-Day Avg101.70

About

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jinhao Du
  • Employees2.27K
  • HeadquartersNo. 268 Lingxiaohua Road, Shanghai, China, 201318, China
  • Websitehttps://www.allist.com.cn

Leadership

  • Mr. Jinhao DuChairman of the Board & GM · b. 1954
  • Mr. Jie HuVice Chairman & Deputy GM · b. 1975
  • Mr. Lin WangFinancial Director · b. 1983
  • Mr. Chen HuangMarketing Manager · b. 1975
  • Mr. Feng XuDeputy GM & Director · b. 1965
  • Ms. Huafeng ShanChief Quality Officer · b. 1974
  • Ms. Shuo LiBoard Secretary · b. 1990
  • Quan GanAccounting Supervisor
  • Mr. Chang Shou GaoChief Technology Officer · b. 1963
  • Mr. Huayong ZhouDeputy Director of R&D · b. 1984

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue7.73M4.62M629.72K560.89K530.09M791.00M2.02B3.56B5.17B
Growth (%)--40.21%-86.37%-10.93%+94409.97%+49.22%+155.14%+76.29%+45.36%
Cost of Revenue240.35K249.58K270.43K161.69K29.95M47.11M110.02M168.99M164.58M
Gross Profit7.49M4.37M359.29K399.19K500.14M743.90M1.91B3.39B5.17B
Gross Margin96.89%94.60%57.06%71.17%94.35%94.04%94.55%95.25%100.00%
Operating Expense46.29M102.63M381.64M310.85M478.32M616.08M1.25B1.75B2.60B
Operating Income-38.80M-98.26M-381.28M-310.45M21.83M127.81M657.67M1.63B2.57B
Operating Margin-502.12%-2126.90%-60547.98%-55350.13%4.12%16.16%32.59%45.95%49.68%
EBITDA-28.37M-85.07M-380.69M-297.46M32.69M146.49M693.37M1.65B2.57B
EBITDA Margin-367.21%-1841.46%-60453.09%-53033.64%6.17%18.52%34.36%46.51%49.64%
Net Income-38.93M-97.39M-397.50M-310.52M18.27M130.52M644.17M1.43B2.18B
Net Income Margin-503.87%-2108.11%-63123.39%-55361.45%3.45%16.50%31.92%40.19%42.18%
R&D37.91M92.49M162.00M177.96M222.59M191.75M313.06M314.49M413.37M
R&D as % of Total Revenue490.65%2001.90%25725.42%31728.85%41.99%24.24%15.51%8.84%7.99%
Interest Expense4.24M6.02M7.28M1.19M605.05K325.32K206.08K65.96K130.20K
Interest Expense % of Total Revenue54.89%130.26%1155.87%212.67%0.11%0.04%0.01%0.00%0.00%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets508.63M375.00M1.33B2.99B3.13B3.44B4.38B5.92B7.90B
Total Liabilities127.37M303.96M144.02M109.01M156.99M255.12M394.22M633.32M-6.50B
Total Equity381.26M71.04M1.18B2.88B2.97B3.19B3.98B5.28B6.50B
Cash58.94M128.61M392.58M365.84M615.36M470.49M1.86B586.99M674.54M
Total Debt60.00M125.00M110.00M12.22M5.39M1.96M1.82M302.50K-
Net Debt1.06M-3.61M-282.58M-353.62M-609.96M-468.54M-1.86B-586.69M-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow10.11M-97.25M-259.37M-196.75M29.29M91.63M674.65M1.57B2.32B
Investing Cash Flow-17.03M39.17M-622.42M-1.74B239.19M-404.21M92.75M-1.84B-
Financing Cash Flow-11.26M122.15M1.15B1.91B-16.97M-3.69M-2.21M-295.05M-
Capital Expenditure1.40M35.99M89.37M88.45M192.25M143.83M67.88M270.22M186.00M
Free Cash Flow8.72M-133.24M-348.74M-285.20M-162.95M-52.21M606.77M1.30B2.14B
Dividends Paid4.26M4.50M33.38M1.19M---292.50M360.00M
FCF to OCF86.20%137.00%134.45%144.96%-556.33%-56.97%89.94%82.74%91.99%
Dividend Paid to FCF48.83%-3.38%-9.57%-0.42%---22.57%16.85%

Earnings

Report DateFeb 25, 2021Apr 28, 2021Aug 24, 2021Oct 29, 2021Feb 25, 2022Apr 26, 2022Aug 25, 2022Oct 28, 2022Dec 31, 2022Apr 26, 2023
EPS Estimate----------
EPS Actual-0.23-0.10-0.080.47-0.26-0.050.110.060.170.17
Surprise----------
TimingPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap50.21B
Enterprise Value46.83B
Trailing P/E18.78
Forward P/E0.00
Price / Sales8.19
Price / Book5.98
EPS5.94
Book Value18.81
Revenue (TTM)6.13B
Gross Profit (TTM)5.87B
EBITDA2.71B
Profit Margin43.67%
Operating Margin48.42%
Return on Equity36.71%
Return on Assets20.29%
Shares Outstanding450.00M
Shares Float224.78M
Beta0.01
Dividend Yield1.08%
Dividend Rate1.20
Payout Ratio16.84%

Dividends

20262×
0.60Sep 2, 20260.60Jun 1, 2026
20252×
0.40Sep 10, 20250.40Jun 3, 2025
20242×
0.25Sep 5, 20240.40May 31, 2024